LONDON (AFX) - SR Pharma PLC said phase I of the clinical trial on using its RNA-interference
product candidate Atu027 RNAi in patients suffering from pancreatic cancer is scheduled to start in 2007.
In a research update, the AIM-listed biopharmaceutical company said its product was more effective in the prevention of metastases than Gemcitabine, an approved drug for palliative treatment.
The company said studies showed the therapeutic efficacy of its product in pre-clinical models of pancreatic cancer when compared to the standard care treatment and said data showed cancer growth was inhibited and prevented metastatic spread, with no adverse events.
COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.